Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cochlear Implantation in a Patient with Neurofibromatosis Type 1 and Profound Hearing Loss: Evidence to Support a Cochlear Site of Lesion

Poissant, Sarah F.*; Megerian, Cliff A.; Hume, Dayna

COCHLEAR IMPLANTS
Buy

Objective To determine the efficacy of cochlear implantation in an individual with neurofibromatosis type 1 and profound hearing loss and to determine, to the extent possible in a living subject, the site of lesion of the hearing loss in an individual with neurofibromatosis type 1.

Study Design Postoperative assessment of an adult male with neurofibromatosis type 1.

Setting The study was completed in the Departments of Otolaryngology and Audiology, University of Massachusetts Medical Center, Massachusetts.

Patients One adult male with neurofibromatosis type 1 and bilateral, chiefly profound, sensorineural hearing loss.

Interventions The subject underwent cochlear implantation as treatment of bilateral, chiefly profound sensorineural hearing loss.

Main Outcome Measures Outcome measures include results of electrical auditory brainstem response testing, electrical compound action potential measures, and speech recognition scores.

Results Results of testing revealed expected latencies of waves II, III, and V of the electrical auditory brainstem response, measurable compound action potentials across virtually the entire length of the electrode array, and high levels of open-set, auditory-only speech understanding.

Conclusions This is the first case report describing the outcome of cochlear implantation in a patient with neurofibromatosis type 1. Composite test results support the absence of VIIIth nerve degeneration or other anomalies, indicating a cochlear site of lesion for the hearing loss in this patient. Based on the results of this investigation, standard cochlear implantation should be considered a viable option and the first line of therapy for the treatment of bilateral, severe to profound sensorineural hearing loss in patients with neurofibromatosis type 1 and normal, VIIIth nerve radiographic findings.

*Department of Communication Disorders, University of Massachusetts, Amherst; †Department of Otolaryngology, University of Massachusetts Medical Center, Worcester; and ‡Department of Audiology, UMass Memorial Rehab Group, Worcester, Massachusetts, U.S.A. C. A. Megerian is presently at the Department of Otolaryngology–Head & Neck Surgery, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.

Address correspondence and reprint requests to Dr. Sarah F. Poissant, University of Massachusetts, Communication Disorders Department, 125 Arnold House, Amherst, MA 01003. Email: spoissant@comdis.umass.edu

© 2003 Otology & Neurotology, Inc.